MPR

Pirtobrutinib Combo Regimen Improves PFS in Relapsed or Refractory CLL/SLL

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Lilly’s Jaypirca racks up fourth Phase III CLL win

Eli Lilly’s Jaypirca (pirtobrutinib) has succeeded in its fourth Phase III trial in chronic lymphocytic leukaemia (CLL). The ...

Eli Lilly's Jaypirca builds case with fourth positive phase 3 trial in blood cancer patients

Eli Lilly and Co. LLY shares were little changed in Monday’s premarket session. The U.S. drug giant shared results from the ...

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/…

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca ...
The American Journal of Managed Care

Quality of Life Impacted By CLL and SLL Diagnosis and Management

Clinical manifestations and impact on patient quality of life amid diagnosis and management of CLL and SLL are discussed. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, ...
The American Journal of Managed Care

Indications and Considerations For BTK Inhibitor Use In CLL and SLL Management

Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, ...
Monthly Prescribing Reference

Jaypirca Gains CLL/SLL Indication Through Accelerated Approval Pathway

The accelerated approval was based on data from the phase 1/2 BRUIN trial that included a subset of 108 patients with CLL/SLL. The Food and Drug Administration (FDA) has granted accelerated approval ...
Cure Today

Treatment Discontinuations Reduced With Jaypirca in CLL, SLL

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
Cure Today

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
Medscape

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The US Food and Drug Administration (FDA) has granted accelerated approval for lisocabtagene maraleucel (liso-cel) for the treatment of certain adults with relapsed or refractory chronic lymphocytic ...
Nasdaq

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
WebMD

Treating Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Copiktra

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...